Positive News SentimentPositive NewsNASDAQ:GNLX Genelux (GNLX) Stock Price, News & Analysis $2.81 -0.28 (-9.06%) (As of 10/17/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends About Genelux Stock (NASDAQ:GNLX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Genelux alerts:Sign Up Key Stats Today's Range$2.75▼$3.0850-Day Range$1.98▼$3.1952-Week Range$1.60▼$20.51Volume101,652 shsAverage Volume184,318 shsMarket Capitalization$96.53 millionP/E RatioN/ADividend YieldN/APrice Target$22.33Consensus RatingBuy Company OverviewGenelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.Read More… The real reason Elon is fully endorsing Trump (Ad)Elon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to humanity, there is a war being waged on Elon Musk. This war has nothing to do with X, Elon’s stance on immigration or his support for Donald Trump. Watch this new documentary and you’ll discover what Elon knows, Genelux Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks47th Percentile Overall ScoreGNLX MarketRank™: Genelux scored higher than 47% of companies evaluated by MarketBeat, and ranked 690th out of 1,012 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingGenelux has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageGenelux has only been the subject of 3 research reports in the past 90 days.Read more about Genelux's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Genelux are expected to decrease in the coming year, from ($0.90) to ($0.98) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Genelux is -2.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Genelux is -2.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGenelux has a P/B Ratio of 3.85. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Genelux's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.03% of the float of Genelux has been sold short.Short Interest Ratio / Days to CoverGenelux has a short interest ratio ("days to cover") of 7.8.Change versus previous monthShort interest in Genelux has recently decreased by 0.88%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGenelux does not currently pay a dividend.Dividend GrowthGenelux does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted4.03% of the float of Genelux has been sold short.Short Interest Ratio / Days to CoverGenelux has a short interest ratio ("days to cover") of 7.8.Change versus previous monthShort interest in Genelux has recently decreased by 0.88%, indicating that investor sentiment is improving. News and Social Media2.7 / 5News SentimentN/A News SentimentGenelux has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Medical companies.Search InterestOnly 2 people have searched for GNLX on MarketBeat in the last 30 days. This is a decrease of -78% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Genelux to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Genelux insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $736,831.00 in company stock.Percentage Held by InsidersOnly 9.30% of the stock of Genelux is held by insiders.Percentage Held by InstitutionsOnly 37.33% of the stock of Genelux is held by institutions.Read more about Genelux's insider trading history. Receive GNLX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Genelux and its competitors with MarketBeat's FREE daily newsletter. Email Address GNLX Stock News HeadlinesGenelux Corporation to Participate in the 2024 Maxim Healthcare Virtual SummitOctober 9, 2024 | globenewswire.comGenelux corp insider sells over $170k in company stockSeptember 15, 2024 | investing.comEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.October 17, 2024 | Paradigm Press (Ad)Genelux Corporation to Present at the H.C. Wainwright Global Investment ConferenceSeptember 3, 2024 | globenewswire.comGenelux started at buy by Roth MKM ahead of Olvi-Vec readoutsAugust 30, 2024 | msn.comRoth MKM Initiates Coverage of Genelux (GNLX) with Buy RecommendationAugust 29, 2024 | msn.comIs Genelux (NASDAQ:GNLX) In A Good Position To Invest In Growth?August 17, 2024 | finance.yahoo.comGenelux Corporation Reports Second Quarter 2024 Financial Results and Provides General Business UpdatesAugust 14, 2024 | globenewswire.comSee More Headlines GNLX Stock Analysis - Frequently Asked Questions How have GNLX shares performed this year? Genelux's stock was trading at $14.01 at the beginning of 2024. Since then, GNLX stock has decreased by 79.9% and is now trading at $2.81. View the best growth stocks for 2024 here. How were Genelux's earnings last quarter? Genelux Co. (NASDAQ:GNLX) announced its earnings results on Wednesday, August, 14th. The company reported ($0.22) EPS for the quarter, missing analysts' consensus estimates of ($0.19) by $0.03. When did Genelux IPO? Genelux (GNLX) raised $16 million in an initial public offering (IPO) on Thursday, January 26th 2023. The company issued 2,500,000 shares at a price of $6.00-$7.00 per share. The Benchmark Company and Brookline Capital Markets acted as the underwriters for the IPO. Who are Genelux's major shareholders? Genelux's top institutional shareholders include LifeSteps Financial Inc. (0.23%), Exchange Traded Concepts LLC (0.19%) and Miracle Mile Advisors LLC (0.12%). Insiders that own company stock include Aladar Szalay, John Thomas, Sean Ryder, Caroline Jewett, Thomas Zindrick, Yong Yu, John W Smither, Joseph Cappello, Doug Samuelson and Qian Zhang. View institutional ownership trends. How do I buy shares of Genelux? Shares of GNLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Genelux own? Based on aggregate information from My MarketBeat watchlists, some other companies that Genelux investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE), Netflix (NFLX) and Palo Alto Networks (PANW). Company Calendar Last Earnings8/14/2024Today10/17/2024Next Earnings (Estimated)11/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:GNLX CUSIPN/A CIK1231457 Webwww.genelux.com Phone805-267-9889FaxN/AEmployees10Year FoundedN/APrice Target and Rating Average Stock Price Target$22.33 High Stock Price Target$32.00 Low Stock Price Target$10.00 Potential Upside/Downside+694.8%Consensus RatingBuy Rating Score (0-4)3.20 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.97) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-28,300,000.00 Net MarginsN/A Pretax Margin-331,724.97% Return on Equity-110.28% Return on Assets-80.53% Debt Debt-to-Equity RatioN/A Current Ratio6.01 Quick Ratio6.01 Sales & Book Value Annual Sales$8,000.00 Price / Sales12,066.14 Cash FlowN/A Price / Cash FlowN/A Book Value$0.73 per share Price / Book3.85Miscellaneous Outstanding Shares34,352,000Free Float31,323,000Market Cap$96.53 million OptionableNot Optionable Beta-1.54 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report This page (NASDAQ:GNLX) was last updated on 10/17/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredRetire off just one stock ticker?ONE AI Stock is All You Need... There are over 6,000 stocks listed in the market right now. They will NOT m...Behind the Markets | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredAdd $2T of Potential Magic to Your PortfolioRevolutionizing a whole $2T entertainment and licensing industry might sound like the stuff of fairytales. But...Elf Labs | SponsoredEquation for Profits: Volatility = OpportunityFREE Intro to Options Class Online Tonight Prosper Trading Academy | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genelux Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Genelux With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.